Profile data is unavailable for this security.
About the company
Suzuken Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in four business segments. The Pharmaceutical Wholesale segment sells pharmaceuticals, diagnostic drugs, and medical equipment and materials, among others. The Pharmaceutical Manufacturing segment manufactures pharmaceuticals and diagnostic drugs and others. The Insurance Pharmacy segment is engaged in dispensing operations based on prescriptions from medical institutions. The Medical-related Service and Others segment is engaged in the provision of manufacturer support services, such as the transportation of medicines and comprehensive support for the distribution of drugs for rare diseases; the nursing services; the manufacture of physiological examination equipment, such as electrocardiographic monitors and blood pressure monitors; as well as other services, such as the sale of medical books.
- Revenue in JPY (TTM)2.37tn
- Net income in JPY27.68bn
- Incorporated1946
- Employees13.43k
- LocationSuzuken Co Ltd8, Higashi Kataha-machi, Higashi-kuNAGOYA-SHI 461-8701JapanJPN
- Phone+81 529612331
- Fax+81 529715837
- Websitehttps://www.suzuken.co.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DocMorris AG | 164.33bn | -19.93bn | 200.19bn | 1.45k | -- | 2.36 | -- | 1.22 | -10.07 | 7.03 | 83.05 | 36.60 | 0.9863 | 11.36 | 10.50 | 667,214.10 | -11.96 | -12.92 | -15.23 | -15.74 | 20.98 | 16.84 | -12.13 | -10.87 | 1.34 | -2.39 | 0.4448 | -- | 4.13 | -4.29 | 31.29 | -- | -2.53 | -- |
| Sigma Healthcare Ltd | 339.32bn | 447.73m | 206.60bn | 156.00 | 322.78 | 2.30 | 61.86 | 0.6089 | 0.004 | 0.004 | 3.34 | 0.5544 | 2.68 | 11.37 | 10.52 | -- | 0.4162 | 0.5734 | 0.625 | 0.9762 | 9.17 | 9.52 | 0.1554 | 0.2022 | 1.86 | 1.59 | 0.1354 | 184.52 | -9.16 | -3.46 | 148.98 | -34.19 | -46.55 | -21.93 |
| Tibet Rhodiola Pharmaceutical Holding Co | 66.96bn | 17.11bn | 244.34bn | 601.00 | 14.28 | 3.42 | -- | 3.65 | 3.23 | 3.23 | 12.64 | 13.49 | 0.7216 | 1.83 | 5.71 | 5,215,189.00 | 18.65 | 12.44 | 25.21 | 15.71 | 93.83 | 90.51 | 25.85 | 20.43 | 2.78 | 7.59 | 0.1294 | 50.41 | 22.69 | 24.98 | 116.56 | 30.01 | -1.48 | 48.97 |
| GuangYuYuan Chinese Herbal Medicn Co Ltd | 23.74bn | -6.93bn | 250.14bn | 1.95k | -- | 6.78 | -- | 10.54 | -0.6628 | -0.6628 | 2.27 | 3.53 | 0.4005 | 0.8061 | 1.31 | 569,846.60 | -12.26 | -1.17 | -16.80 | -1.67 | 69.24 | 71.94 | -30.62 | -3.27 | 1.55 | -18.71 | 0.1474 | -- | 16.44 | -3.17 | -26.08 | -- | -50.29 | -- |
| Toho Holdings Co Ltd | 1.45tn | 17.57bn | 279.05bn | 7.70k | 15.08 | 0.953 | 11.52 | 0.1924 | 242.08 | 242.08 | 20,008.50 | 3,831.19 | 1.81 | 14.05 | 4.05 | 188,375,100.00 | 2.20 | 1.83 | 6.09 | 4.35 | 7.94 | 8.60 | 1.21 | 0.9786 | 1.05 | -- | 0.1298 | 18.14 | 9.67 | 2.73 | 1.88 | -1.07 | -22.49 | 1.30 |
| China Medical System Holdings Ltd | 171.17bn | 51.29bn | 341.84bn | 5.62k | 6.67 | 1.03 | 6.12 | 2.00 | 1.06 | 1.06 | 3.54 | 6.85 | 0.4517 | 3.42 | 5.32 | -- | 13.44 | 18.44 | 15.70 | 21.14 | 76.24 | 75.47 | 29.76 | 34.26 | 3.98 | -- | 0.0772 | 39.76 | -12.43 | 8.08 | -26.33 | 5.35 | -- | 5.19 |
| Suzuken Co Ltd | 2.37tn | 27.68bn | 351.86bn | 13.43k | 13.43 | 0.8643 | 9.68 | 0.1484 | 336.97 | 336.97 | 28,802.96 | 5,236.47 | 1.82 | 12.94 | 4.05 | 176,574,900.00 | 2.12 | 1.77 | 6.33 | 4.64 | 7.75 | 8.05 | 1.17 | 0.9199 | 0.9883 | -- | 0.00 | 31.44 | 3.38 | 1.74 | 41.35 | 1.57 | 17.43 | 5.92 |
| China Meheco Group Co Ltd | 864.63bn | 12.03bn | 356.96bn | 8.31k | 29.67 | 1.49 | -- | 0.4129 | 0.3764 | 0.3764 | 27.05 | 7.48 | 1.13 | 5.58 | 2.76 | 4,868,542.00 | 2.05 | 4.09 | 4.44 | 9.37 | 11.07 | 15.92 | 1.81 | 3.38 | 1.16 | 21.23 | 0.3262 | 38.19 | 3.75 | 4.37 | 13.70 | -10.94 | 12.63 | -4.53 |
| Alfresa Holdings Corporation | 2.83tn | 31.84bn | 447.26bn | 11.77k | 13.52 | 0.888 | 9.87 | 0.1582 | 163.14 | 163.14 | 14,454.60 | 2,483.23 | 1.92 | 15.08 | 4.12 | 240,225,700.00 | 2.17 | 2.47 | 6.17 | 6.52 | 7.24 | 7.34 | 1.13 | 1.24 | 1.03 | -- | 0.0607 | 33.25 | 4.27 | 0.7057 | -19.87 | -6.24 | 15.54 | 7.89 |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 05 Dec 2023 | 10.22m | 13.15% |
| Silchester International Investors LLPas of 20 Feb 2024 | 5.99m | 7.71% |
| BlackRock Advisors (UK) Ltd.as of 05 Dec 2023 | 5.38m | 6.92% |
| Nomura Asset Management Co., Ltd.as of 29 Mar 2024 | 2.45m | 3.16% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 2.35m | 3.03% |
| BlackRock Advisors LLCas of 05 Dec 2023 | 1.40m | 1.80% |
| BlackRock (Netherlands) BVas of 05 Dec 2023 | 1.35m | 1.74% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.20m | 1.54% |
| Nikko Asset Management Co., Ltd.as of 05 Apr 2024 | 1.15m | 1.48% |
| Daiwa Asset Management Co. Ltd.as of 29 Mar 2024 | 1.12m | 1.45% |
